Humans ; Myocardial Infarction ; physiopathology ; therapy ; Myocardial Reperfusion

Drug-Eluting Stents ; Humans ; Percutaneous Coronary Intervention ; methods

Angioplasty, Balloon, Coronary ; Humans

Angioplasty, Balloon, Coronary ; Chronic Disease ; Coronary Occlusion ; therapy ; Humans

Angioplasty, Balloon, Coronary ; Coronary Occlusion ; diagnostic imaging ; therapy ; Fluoroscopy ; adverse effects ; Humans ; Male ; Middle Aged ; Radiodermatitis ; etiology ; Treatment Failure

Adult ; Aged ; Aged, 80 and over ; Angioplasty, Balloon, Coronary ; Emergency Treatment ; Female ; Humans ; Male ; Middle Aged ; Tachycardia ; therapy

Objective To investigate the protective effect of Gingko Biloba extract (GBE) on acute lung hemorrhage induced by Lipopolysaccharide(LPS) in newborn rats. Methods 1. Acute lung hemorrhage models were reproduced by intraperitoneal injection with LPS (5 mg/kg). 2. Thirty two rats were randomly divided into 4 groups,GBE groups (4 mg/kg,8 mg/kg, 16 mg/kg) and LPS group 5 mg/kg. Results In group LPS, extensive lung hemorrhage was observed after 4 hours of injection . TNF - ? iung content was obvious in LPS group. The expression of lung nuclear factor(NF-kB )immunohistochemistry wasobvious. While the parameters were obviously attenuated by GBE before LPS. Conclusion GBE may be useful in the treatment of acute pulmonary inflammatory disease.

Clinical predictors of ST-segment elevation myocardial infarction (STEMI) patients may guide clinicians to select the type of treatment. Four articles published in present issue made an in-depth analysis of the data collected recent years from Cardiovascular Intervention Procedures Database of Chinese military hospitals, explored the effects of gender, preoperative severity of target-vessel stenosis, establishment of chest pain center and intra-aortic balloon pump on in-hospital mortality of STEMI patients, which may be helpful for clinicians to individualize treatment, further optimize reperfusion strategy, and improve the clinical efficacy and the prognosis of STEMI patients.

Antithrombotic therapy is the cornerstone of the treatment of coronary heart disease. To optimize antithrombotic therapy is one of ongoing efforts made by cardiovascular physicians. The randomized controlled clinical research of high quality in the field of antithrombotic therapy for coronary heart disease is still lacking in our country at present, and it become an important problem to be urgently solved in China. As there are studies with rich research data on antithrombotic therapy for cardiovascular disease domestically, and the differences in the problems involved between eastern and western populations, a preliminary exploration had been done in 2012 in the research center where the author is serving. This paper chiefly reviews the problems of major concern in antithrombotic therapy, our present situation, and treatment strategy based on our experience in clinical research for years.